Published in Vaccine Weekly, September 13th, 1999
The dramatic treatment of a dying patient for the first time shows adoptive immunotherapy is possible in organ transplant recipients. Making this breakthrough all the more remarkable is that it was supposed to be impossible.
The patient originally was negative for Epstein-Barr virus (EBV) infection. After receiving a lung transplant and concomitant immunosuppressive therapy, however, he became EBV-positive and developed active posttransplant lymphoproliferative disease (PTLD). Adoptive transfer of autologous, EBV-sensitized, cytotoxic lymphocytes (CTLs) resulted in extensive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.